Burkitt Lymphoma - Pipeline Review H1 2015

Burkitt Lymphoma - Pipeline Review H1 2015

May 2015 Global Markets Direct Lymphoma83 Pages Price :
$ 2000
Burkitt Lymphoma - Pipeline Review H1 2015

Summary

Global Markets Directs Burkitt Lymphoma - Pipeline Review H1 2015 provides an overview of the Burkitt Lymphomas therapeutic pipeline

This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action (MoA) route of administration (RoA) and molecule type along with latest updates and featured news and press releases it also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3000 indications The report is built using data and information sourced from Global Markets Directs proprietary databases Company/University websites SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources put together by Global Markets Directs team Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information Additionally processes including live news & deals tracking browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
- The report reviews key pipeline products under drug profile section which includes product description MoA and R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Burkitt Lymphoma pipeline on the basis of target MoA route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information analysis and insights to formulate effective R&D development strategies
- identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
introduction 5
Global Markets Direct Report Coverage 5
Burkitt Lymphoma Overview 6
Therapeutics Development 7
Pipeline Products for Burkitt Lymphoma - Overview 7
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 8
Burkitt Lymphoma - Therapeutics under Development by Companies 9
Burkitt Lymphoma - Therapeutics under investigation by Universities/institutes 10
Burkitt Lymphoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Burkitt Lymphoma - Products under Development by Companies 13
Burkitt Lymphoma - Products under investigation by Universities/institutes 14
Burkitt Lymphoma - Companies involved in Therapeutics Development 15
AstraZeneca PLC 15
Constellation Pharmaceuticals inc 16
Karyopharm Therapeutics inc 17
Millennium Pharmaceuticals inc 18
Pharmacyclics inc 19
Seattle Genetics inc 20
Burkitt Lymphoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
alisertib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AZD-6738 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
denintuzumab mafodotin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ibrutinib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
selinexor - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SH-7129 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SH-7133 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SH-7139 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to inhibit BET for Cancer - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Burkitt Lymphoma - Recent Pipeline Updates 55
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Burkitt Lymphoma H1 2015 7
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis H1 2015 8
Number of Products under Development by Companies H1 2015 9
Number of Products under investigation by Universities/institutes H1 2015 10
Comparative Analysis by Clinical Stage Development H1 2015 11
Comparative Analysis by Early Stage Development H1 2015 12
Products under Development by Companies H1 2015 13
Products under investigation by Universities/institutes H1 2015 14
Burkitt Lymphoma - Pipeline by AstraZeneca PLC H1 2015 15
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals inc H1 2015 16
Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics inc H1 2015 17
Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals inc H1 2015 18
Burkitt Lymphoma - Pipeline by Pharmacyclics inc H1 2015 19
Burkitt Lymphoma - Pipeline by Seattle Genetics inc H1 2015 20
Assessment by Monotherapy Products H1 2015 21
Number of Products by Stage and Target H1 2015 23
Number of Products by Stage and Mechanism of Action H1 2015 25
Number of Products by Stage and Route of Administration H1 2015 27
Number of Products by Stage and Molecule Type H1 2015 29
Burkitt Lymphoma Therapeutics - Recent Pipeline Updates H1 2015 55

List of Figures
Number of Products under Development for Burkitt Lymphoma H1 2015 7
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis H1 2015 8
Number of Products under Development by Companies H1 2015 9
Comparative Analysis by Clinical Stage Development H1 2015 11
Comparative Analysis by Early Stage Products H1 2015 12
Assessment by Monotherapy Products H1 2015 21
Number of Products by Top 10 Targets H1 2015 22
Number of Products by Stage and Top 10 Targets H1 2015 23
Number of Products by Top 10 Mechanism of Actions H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions H1 2015 25
Number of Products by Top 10 Routes of Administration H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration H1 2015 27
Number of Products by Top 10 Molecule Types H1 2015 28
Number of Products by Stage and Top 10 Molecule Types H1 2015 29

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top